<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03332264</url>
  </required_header>
  <id_info>
    <org_study_id>SP01</org_study_id>
    <nct_id>NCT03332264</nct_id>
  </id_info>
  <brief_title>Sequent Please Drug Coated Balloons Versus Primary Stent Application in Long SFA Lesions</brief_title>
  <acronym>SPORTS</acronym>
  <official_title>Sequent Please Drug Coated Balloons Versus Primary Stent Application in Long SFA Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InnoRa GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>InnoRa GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with peripheral artery disease will be treated with either drug coated balloon&#xD;
      catheter, drug coated stent or uncoated stent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with chronic stenotic or occlusive atherosclerotic disease and lesions of at least&#xD;
      13 cm length in the SFA or Arteria poplitea segment 1 will be randomized to either treatment&#xD;
      with paclitaxel coated balloon catheter, paclitaxel coated stent or bare nitinol stent.&#xD;
      Vessel patency will be evaluated by quantitative angiography after 12 months. Clinical&#xD;
      follow-ups will be done until 36 months post-intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 30, 2017</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Actual">November 19, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Vessel patency will be compared by quantitative angiography at 12 months in patients who have been treated either with paclitaxel coated balloon catheter, paclitaxel coated stent or bare metal stent in femoropopliteal arteries</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Corelab will be masked for the bare metal and paclitaxel coated stent arm.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percent diameter stenosis at 1 year post intervention in successfully treated patients</measure>
    <time_frame>12 +/- 2 months</time_frame>
    <description>by quantitative angiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late Lumen Loss</measure>
    <time_frame>12 months</time_frame>
    <description>by quantitative angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis</measure>
    <time_frame>6,12, 24, 36 months</time_frame>
    <description>by DUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>6, 12, 24, 36 months</time_frame>
    <description>number of re-interventions at target lesion</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Event-free survival</measure>
    <time_frame>6, 12, 24, 36 months</time_frame>
    <description>absence from target lesion revascularization, amputations and death</description>
  </other_outcome>
  <other_outcome>
    <measure>Walking distance</measure>
    <time_frame>6, 12, 24, 36 months</time_frame>
    <description>assessed in m and compared to baseline value</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Stenosis</condition>
  <condition>Occlusion</condition>
  <condition>Restenosis</condition>
  <arm_group>
    <arm_group_label>Drug coated balloon catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTA with paclitaxel coated &quot;SeQuent Please OTW&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug coated stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PTA with paclitaxel coated &quot;Eluvia Vascular Stent System&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uncoated stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PTA with bare nitinol stent (as commonly used in site)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SeQuent Please OTW</intervention_name>
    <description>Dilatation of occluded or highly stenosed vessel with paclitaxel-coated balloon catheter</description>
    <arm_group_label>Drug coated balloon catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Eluvia Vascular Stent System</intervention_name>
    <description>Dilatation of occluded or highly stenosed vessel with paclitaxel-coated stent</description>
    <arm_group_label>Drug coated stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nitinol stent</intervention_name>
    <description>Dilatation of occluded or highly stenosed vessel with uncoated bare nitinol stent</description>
    <arm_group_label>Uncoated stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PAOD and Rutherford classes 2 - 4 (pain-free walking distance &lt;500 m)&#xD;
&#xD;
          -  eligible for peripheral revascularization by means of PTA&#xD;
&#xD;
          -  peripheral lesions in the superficial femoral artery (SFA) and / or the PI-segment of&#xD;
             the popliteal artery (A.pop.)&#xD;
&#xD;
          -  minimum diameter stenosis of ≥70%&#xD;
&#xD;
          -  treatment length at least 15 cm (lesion length at least 13 cm)&#xD;
&#xD;
          -  maximum of lesions to be treated should be 2 (all treated lesions should be treated&#xD;
             within the randomization to the study group, i.e. either coated balloon catheters or&#xD;
             coated stents or bare nitinol stents); in case of two lesions matching the eligibility&#xD;
             criteria, the one presenting the worst attributes (length and stenosis degree) should&#xD;
             be chosen as target lesion&#xD;
&#xD;
          -  long diffuse stenosis with or without occlusions may only be divided in separate&#xD;
             lesions if non-stenotic (i.e. &lt;50% stenosis) segments in between the lesions extent to&#xD;
             &gt;2 cm, otherwise vessel segments will be treated as a single extended lesion&#xD;
&#xD;
          -  eligible for an operative vascular intervention in case of complications during the&#xD;
             PTA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Rutherford class 1,5 or 6&#xD;
&#xD;
          -  more than two stenotic lesions in the target vessel requiring treatment&#xD;
&#xD;
          -  inflow lesion (proximal to the study lesion) with flow limitation not being&#xD;
             successfully treated prior to the study lesion&#xD;
&#xD;
          -  in-stent restenosis of the study lesion&#xD;
&#xD;
          -  strongly calcified lesions with circumferential presence of calcifications and a&#xD;
             lesion calcification length of &gt;4 cm&#xD;
&#xD;
          -  reference vessel diameter &lt;4 mm and &gt;6 mm&#xD;
&#xD;
          -  guide wire could not be successfully advanced across the lesion&#xD;
&#xD;
          -  lesions below the knee requiring treatment&#xD;
&#xD;
          -  target lesion is located in the PII-segment of the popliteal artery (A.pop.) or within&#xD;
             a bypass graft&#xD;
&#xD;
          -  acute thrombosis of the study lesion requiring lysis or thrombectomy prior to the&#xD;
             treatment of the study lesion&#xD;
&#xD;
          -  potential loss of leg due to critical or acute ischemia&#xD;
&#xD;
          -  no patent distal run-off vessel&#xD;
&#xD;
          -  medical reason against double anti-platelet therapy in anti-coagulated patient, e.g.,&#xD;
             receiving coumarine or conditions which prevent the intake of the double anti-platelet&#xD;
             therapy for two months&#xD;
&#xD;
          -  female patient who is pregnant or lactating&#xD;
&#xD;
          -  under 18 years of age&#xD;
&#xD;
          -  patients under administrative or judicial custody (§20 Act on medical Devices,&#xD;
             Germany)&#xD;
&#xD;
          -  expected life span of less than 24 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar Tepe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RoMed Klinikum Rosenheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RoMed Klinikum</name>
      <address>
        <city>Rosenheim</city>
        <state>Bayern</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Arnsberg, Karolinen-Hospital</name>
      <address>
        <city>Arnsberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ihre-Radiologen Standort Franziskus-Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ihre-Radiologen Standort Jüdisches Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonissenkrankenhaus Flensburg</name>
      <address>
        <city>Flensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SANA Kliniken Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätklinikum Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>November 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAOD</keyword>
  <keyword>drug coated balloon</keyword>
  <keyword>drug coated stent</keyword>
  <keyword>percutaneous transluminal angioplasty (PTA)</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

